Explore how proteomics is revolutionizing our understanding of drug resistance by studying proteins rather than just genes.
Discover how restoring wild-type p53 activity in p53-null HL-60 cells transforms drug-resistant cancer cells into therapy-responsive targets, offering new hope for cancer treatment.
Research on the stepwise evolution of docetaxel resistance in breast cancer cells and emerging strategies to combat it.